Overview
The first-line (1L) treatment landscape for locally advanced or metastatic urothelial cancer (Ia/mUC) has rapidly evolved, and real-world evidence on adverse events associated with novel 1L therapies is limited. This study aims to fill those gaps, investigating the real-world treatment-emergent adverse events (rwTEAE) patients experience during 1L treatments for locally advanced or metastatic urothelial carcinoma (la/mUC).
Using real-world data from the US nationwide Flatiron Health EHR-derived database, researchers analyzed records of >5,200 patients, using machine learning to identify 30 specific side effects documented by clinicians during the 1L treatment regimen. The occurrence of rwTEAEs varied considerably across the different 1L regimens examined in the study overall and when adjusting for different durations of time on therapy.
Why this matters
For patients with la/mUC, navigating treatment options can be challenging. This study improves our understanding of the real-world safety of 1L therapies which can be an important aspect of treatment decision-making for patients and their providers.